Showing 951-960 of 5659 results for "".
GLP-1 Receptor Agonists: Current Roles in Medicine
https://practicaldermatology.com/issues/novemberdecember-2025/glp-1-receptor-agonists-current-roles-in-medicine/48897/In recent years, the popularity of glucagon-like peptide 1 receptor agonists (GLP-1RAs) has skyrocketed, along with interest in clinical applications beyond diabetes and weight management. Here, we present a brief review of GLP-1RAs, including a history, a look at the mechanism of action, pivotal reGLP-1 Receptor Agonists and the Aesthetic Patient: Considerations for the Dermatologist
https://practicaldermatology.com/issues/novemberdecember-2025/glp-1-receptor-agonists-and-the-aesthetic-patient/48900/The impact of glucagon-like peptide-1 agonists (GLP-1), such as semaglutide, tirzepatide and liraglutide, has transformed the healthcare industry and, in particular, aesthetic dermatology. The most common intended use of these medications, namely diabetes management and weight loss, can lead to a muComorbidities in Atopic Dermatitis
https://practicaldermatology.com/issues/october-2025/comorbidities-in-atopic-dermatitis/39756/In this article, as part of a series on comorbidities associated with immune-mediated skin diseases, we explore the spectrum of comorbidities linked to AD.Collagen in Atopic Dermatitis
https://practicaldermatology.com/topics/atopic-dermatitis/collagen-atopic-dermatitis/27167/Kripa Ahuja, MS, and Peter Lio, MD, review a 2024 study from Szalsus et al. looking at the role of collagens in atopic dermatitis (AD).Curing the Blues: Resolution of the Tyndall Effect Through Removal of a Misplaced NASHA Filler with Hyaluronidase
https://practicaldermatology.com/topics/general-topics/PD0509_11-php/22833/Implantation of NASHA fillers too superficially can produce the Tyndall effect. Besides aesthetic elegance, longevity after injection and an excellent safety record, a significant advantage of NASHA fillers is that they are reversible when misplaced.Roflumilast Cream, 0.15%, for Atopic Dermatitis
https://practicaldermatology.com/issues/december-2024/Roflumilast-Cream-Atopic-Dermatitis/32840/Atopic dermatitis (AD) is a chronic, persistent inflammatory condition that significantly disrupts the quality of life of patients diagnosed with it. Moreover, AD presents challenges for clinicians when counseling patients on the management of their condition. Application frequency, treatment formulUnderstanding the MOA of NEMLUVIO®: Targeting IL-31 Signaling in Neuroimmune Skin Diseases
https://practicaldermatology.com/programs/nemluvio-peer-network/understanding-the-moa-of-nemluvio-targeting-il-31-signaling-in-neuroimmune-skin-diseases/37128/Watch Dr Peter Lio as he explains the role of IL-31, a key neuroimmune cytokine, in AD and PN and provides an in depth overview of the mechanism of action for NEMLUVIO®.Physician Spotlight: Ellen Marmur, MD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-ellen-marmur-md/20581/Perspectives on head-to-toe beauty.High Risk SCC: What Factors Predict Recurrence and Metastasis?
https://practicaldermatology.com/topics/general-topics/PD1208_12-php/22609/Data shed light on risk factors associated with aggressive SCC, allowing dermatologists to identify and properly follow high-risk patients.How NEMLUVIO® Works
https://reachmd.com/programs/nemluvio-peer-network/how-nemluvio-works/37226/Learn how NEMLUVIO® works to directly block IL-31RA from Dr Peter Lio, a leading dermatologist, with extensive experience in treating neuroimmune skin diseases.